Acticor biotech

Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, a first-in-class drug candidate for the treatment of cardiovascular emergencies and acute thrombotic diseases. The company primarily focuses on the acute phase of ischemic stroke and ST-elevation myocardial infarction (STEMI). As a spin-off from the French National Institute of Health and Medical Research (INSERM), it aims to provide safe therapeutic options for patients during the acute phase of these conditions.